Clinical Trials Browser

Chromosome 17 deletion × venetoclax × 90 days × Clear all

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell